A Phase III, Multicenter, Randomized, Double Masked, Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne) Photodynamic Therapy in Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration
收藏Mendeley Data2024-01-31 更新2024-06-30 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00005655/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is a phase III, multicenter, randomized, double-masked, active treatment-controlled study of intravitreally administered ranibizumab compared with verteporfin (Visudyne) photodynamic therapy (PDT) in treating subfoveal neovascular mascular degeneration.
创建时间：
2024-01-31
